HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control
- PMID: 31505258
- PMCID: PMC6804684
- DOI: 10.1016/j.pvr.2019.100184
HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control
Abstract
Intense research activity in HPV modelling over this decade has prompted the development of additional guidelines to those for general modelling. A specific framework is required to address different policy questions and unique complexities of HPV modelling. HPV-FRAME is an initiative to develop a consensus statement and quality-based framework for epidemiologic and economic HPV models. Its development involved an established process. Reporting standards have been structured according to seven domains reflecting distinct policy questions in HPV and cancer prevention and categorised by relevance to a population or evaluation. Population-relevant domains are: 1) HPV vaccination in pre-adolescent and young adolescent individuals; 2) HPV vaccination in older individuals; 3) targeted vaccination in men who have sex with men; 4) considerations for individuals living with HIV and 5) considerations for low- and middle-income countries. Additional considerations applicable to specific evaluations are: 6) cervical screening or integrated cervical screening and HPV vaccination approaches and 7) alternative vaccine types and alternative dosing schedules. HPV-FRAME aims to promote the development of models in accordance with an explicit framework, to better enable target audiences to understand a model's strength and weaknesses in relation to a specific policy question and ultimately improve the model's contribution to informed decision-making.
Keywords: Cervical screening; Guidelines; Human papillomavirus; Modelling; Prevention; Vaccination.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.
Figures
Similar articles
-
Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.Vaccine. 2013 Dec 29;31 Suppl 5:F60-72. doi: 10.1016/j.vaccine.2012.07.093. Vaccine. 2013. PMID: 24331749
-
Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).Vaccine. 2013 Dec 30;31 Suppl 6:G65-77. doi: 10.1016/j.vaccine.2012.06.096. Vaccine. 2013. PMID: 24331822
-
Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.Vaccine. 2013 Dec 31;31 Suppl 7:H46-58. doi: 10.1016/j.vaccine.2013.06.043. Vaccine. 2013. PMID: 24332297
-
Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.Clin Microbiol Infect. 2012 Oct;18 Suppl 5:64-9. doi: 10.1111/j.1469-0691.2012.03946.x. Epub 2012 Aug 6. Clin Microbiol Infect. 2012. PMID: 22862799 Review.
-
Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines.Int J Cancer. 2016 Aug 1;139(3):510-7. doi: 10.1002/ijc.30063. Epub 2016 Mar 22. Int J Cancer. 2016. PMID: 26916230 Free PMC article. Review.
Cited by
-
Cost-effectiveness studies of HPV self-sampling: A systematic review.Prev Med. 2020 Mar;132:105953. doi: 10.1016/j.ypmed.2019.105953. Epub 2020 Jan 3. Prev Med. 2020. PMID: 31911163 Free PMC article.
-
Inclusion of marginalized populations in HPV vaccine modeling: A systematic review.Prev Med. 2024 May;182:107941. doi: 10.1016/j.ypmed.2024.107941. Epub 2024 Mar 24. Prev Med. 2024. PMID: 38522627 Free PMC article.
-
Upper age limits for US male human papillomavirus vaccination for oropharyngeal cancer prevention: a microsimulation-based modeling study.J Natl Cancer Inst. 2023 Apr 11;115(4):429-436. doi: 10.1093/jnci/djad009. J Natl Cancer Inst. 2023. PMID: 36655795 Free PMC article.
-
The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost-effectiveness of human papillomavirus screening with self-collection and digital registry support.Int J Cancer. 2021 Dec 15;149(12):1997-2009. doi: 10.1002/ijc.33759. Epub 2021 Aug 25. Int J Cancer. 2021. PMID: 34363620 Free PMC article.
-
Where Do We Go From Here? A Framework for Using Susceptible-Infectious-Recovered Models for Policy Making in Emerging Infectious Diseases.Value Health. 2021 Jul;24(7):917-924. doi: 10.1016/j.jval.2021.03.005. Epub 2021 May 10. Value Health. 2021. PMID: 34243834 Free PMC article.
References
-
- Globocan Cancer Fact Sheets . 2018. Cervical Cancer, Estimated Incidence, Mortality and Prevalence Worldwide in.http://gco.iarc.fr/today/data/factsheets/cancers/23-Cervix-uteri-fact-sh...
-
- Novakovic D., Cheng A.T.L., Zurynski Y., Booy R., Walker P.J., Berkowitz R. A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program. J. Infect. Dis. 2018;217:208–212. - PubMed
-
- Marsico M., Mehta V., Chastek B., Liaw K.L., C Derkay C. Estimating the incidence and prevalence of juvenile-onset recurrent respiratory papillomatosis in publicly and privately insured claims databases in the United States. Sex. Transm. Dis. 2014;41:300–305. - PubMed
-
- Omland T., Akre H., Vårdal M., Brøndbo K. Epidemiological aspects of recurrent respiratory papillomatosis: a population-based study. The Laryngoscope. 2012;122:1595–1599. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources